The study yielded four main findings: (1) it established a classification framework for CRC, dividing it into five subtypes; (2) this classification framework demonstrated pan-cancer conservativeness, making it applicable to various types of cancers; (3) the framework was effective in predicting the immunotherapy outcomes for CRC, contributing to precision medicine in CRC; and (4) the study revealed the mechanism by which aDCs promote immunotherapy through CD8+T cells, offering new intervention targets for subsequent research. The gene discussed is CD8A; the disease is cancer.